Literature DB >> 32303524

Diffuse large B-cell lymphoma of the rectum in a patient with Crohn's disease.

Adam Joseph Hardy1, Ionica Stoica2, David Edward Kearney3, Diarmuid S O'Riordain4.   

Abstract

A 62-year-old man presented to our institute with diarrhoea and dysuria on a background of subtotal colectomy and end ileostomy and biological therapy for Crohn's disease. He was diagnosed with urinary tract infection and acute kidney injury (AKI). Renal ultrasound suggested left hydronephrosis, with renal protocol computed tomography (CT) showing a large pelvic mass. Magnetic resonance imaging (MRI) of the pelvis demonstrated a rectal tumour invading the bladder and compressing both ureters. He underwent cystoscopy, flexible sigmoidoscopy and positron emission tomography-CT and was diagnosed with stage IV non-Hodgkin's diffuse large B-cell lymphoma. He was treated primarily with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin and prednisolone chemotherapy regimen. He had ongoing urosepsis before admission for pelvic exenteration. He underwent cystoprostatectomy, excision of rectal stump and formation of ileal conduit. Histology showed no signs of residual malignancy. One year later, the patient was admitted to the intensive care unit with aspiration pneumonia, urosepsis and AKI. Despite maximal therapy, he developed multiorgan failure and passed away. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer intervention; colon cancer; inflammatory bowel disease; malignant disease and immunosuppression; surgical oncology

Mesh:

Substances:

Year:  2020        PMID: 32303524      PMCID: PMC7199099          DOI: 10.1136/bcr-2018-228818

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

Review 1.  The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents.

Authors:  John H Kwon; Richard J Farrell
Journal:  Crit Rev Oncol Hematol       Date:  2005-10       Impact factor: 6.312

2.  Primary intestinal lymphoma in patients with inflammatory bowel disease: a descriptive series from the prebiologic therapy era.

Authors:  Stefan D Holubar; Eric J Dozois; Edward V Loftus; Swee H Teh; Luis A Benavente; W Scott Harmsen; Bruce G Wolff; Robert R Cima; David W Larson
Journal:  Inflamm Bowel Dis       Date:  2010-11-04       Impact factor: 5.325

Review 3.  How to improve the safety of biologic therapy in Crohn's disease.

Authors:  I Ferkolj
Journal:  J Physiol Pharmacol       Date:  2009-12       Impact factor: 3.011

Review 4.  Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.

Authors:  C J M Williams; L Peyrin-Biroulet; A C Ford
Journal:  Aliment Pharmacol Ther       Date:  2014-01-20       Impact factor: 8.171

Review 5.  Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.

Authors:  Sara Renna; Mario Cottone; Ambrogio Orlando
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.

Authors:  Gerald A Dayharsh; Edward V Loftus; William J Sandborn; William J Tremaine; Alan R Zinsmeister; Thomas E Witzig; William R Macon; Lawrence J Burgart
Journal:  Gastroenterology       Date:  2002-01       Impact factor: 22.682

Review 7.  Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.

Authors:  Yuehong Chen; Jianhong Sun; Yuan Yang; Yupeng Huang; Gang Liu
Journal:  Clin Rheumatol       Date:  2015-11-16       Impact factor: 2.980

8.  Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Authors:  James R Cerhan; Anne Kricker; Ora Paltiel; Christopher R Flowers; Sophia S Wang; Alain Monnereau; Aaron Blair; Luigino Dal Maso; Eleanor V Kane; Alexandra Nieters; James M Foran; Lucia Miligi; Jacqueline Clavel; Leslie Bernstein; Nathaniel Rothman; Susan L Slager; Joshua N Sampson; Lindsay M Morton; Christine F Skibola
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

9.  Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

Authors:  David S Kotlyar; James D Lewis; Laurent Beaugerie; Ann Tierney; Colleen M Brensinger; Javier P Gisbert; Edward V Loftus; Laurent Peyrin-Biroulet; Wojciech C Blonski; Manuel Van Domselaar; Maria Chaparro; Sandipani Sandilya; Meenakshi Bewtra; Florian Beigel; Livia Biancone; Gary R Lichtenstein
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-28       Impact factor: 11.382

10.  Primary colorectal lymphoma - A single centre experience.

Authors:  R Tevlin; J O Larkin; J M P Hyland; P R O'Connell; D C Winter
Journal:  Surgeon       Date:  2014-03-30       Impact factor: 2.392

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.